Compare Ginkgo Bioworks Holdings Inc (DNA) vs T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs T-Rex 2X Inverse MSTR Daily Target ETF — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while T-Rex 2X Inverse MSTR Daily Target ETF trades at $2.62 (market cap $94.46M). The key difference: Ginkgo Bioworks Holdings Inc is far larger — about 8.1× T-Rex 2X Inverse MSTR Daily Target ETF's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and T-Rex 2X Inverse MSTR Daily Target ETF for 8 Days on average.
| DNA | MSTZ | |
|---|---|---|
Market Cap | $763.64M | $94.46M |
Volume | 3,204,177 | 104,717,733 |
Sector | Health | Leveraged / Inverse |
52-Week High | $15.83 | $27.92 |
52-Week Low | $5.48 | $2.29 |
Typical Hold Time | 7 Days | 8 Days |
Enterprise Value | $865.59M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with negative cash flow. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting ongoing strategic initiatives despite financial challenges.
The outlook remains speculative given persistent losses and cash burn, though analyst consensus is divided. Key risks include execution on revenue growth and path to profitability. Upside depends on successful commercialization of its biotech platform and partnerships, but high volatility and fundamental weakness warrant caution for investors.
MSTZ trades at $2.73, up 2.63% today, but technical indicators show a bearish trend with moving averages signaling caution. The stock lacks available fundamental data for key valuation and profitability metrics, making financial health assessment challenging. Recent ETF performance coverage highlights market volatility but provides no direct company-specific news.
The outlook is clouded by missing financials and bearish technicals. Investment opportunity hinges on future earnings visibility and competitive positioning. Key risks include potential weak fundamentals, market volatility, and lack of analyst coverage, requiring careful due diligence before consideration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →
